Pfizer (PFE) announces positive topline Phase 2 results for next-generation CDK4 inhibitor, Atirmociclib, in second-line metastatic breast cancer
Importance
Level 1
#PFIZER INC#PFE.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#PFE#US EQUITIES